novartis.com — Scour · Scour

novartis.com

11 posts in the last 30 days

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

novartis.com·8h

Full Circle: A Story of Growth, Purpose and Coming Home to Novartis

novartis.com·2d

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

novartis.com·2d

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

novartis.com·2d

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

novartis.com·3d

Novartis withdraws EMA application for adding new indication for Pluvicto®

novartis.com·6d

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

novartis.com·6d

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

novartis.com·6d

New long term social impact and sustainability targets

novartis.com·2w

Working with communities to close gaps in heart disease and cancer care

novartis.com·3w

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

novartis.com·3w

Log in to enable infinite scrolling